| ||||||||||||||
|
|
|||||||||||||



Departments of *Anesthesiology and
Neurosurgery, Virginia Mason Medical Center, Seattle, Washington
Address correspondence to Dan J. Kopacz, MD, Department of Anesthesiology, Virginia Mason Medical Center, 1100 Ninth Ave., Mailstop B2-AN, Seattle, WA 98111. Address e-mail to anedjk{at}vmmc.org
| Abstract |
|---|
|
|
|---|
IMPLICATIONS: The addition of epinephrine 1:400,000 or 1:200,000 to epidural 0.5% levobupivacaine reduces the resultant serum levobupivacaine levels without altering the duration of sensory blockade. All solutions were well tolerated and effective in producing epidural anesthesia for patients undergoing lumbar spine surgery.
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
The sample size was determined on the basis of estimations of the primary efficacy end pointthe mean duration of bilateral sensory anesthesia above the T10 dermatome (minimum block necessary to initiate and complete surgery). By using previously published data for racemic bupivacaine with epinephrine (SD of 60 min for all groups) (4) and assuming a mean difference between the Plain and Epinephrine-Containing groups of 45 min as clinically significant, 36 patients per group were considered necessary to detect statistical significance (
= 0.05, two sided) with power (1 - ß) = 80%. Allowing for withdrawals, 117 patients were entered into the study.
After an IV infusion of 500 mL of lactated Ringers solution, all patients were premedicated with IV midazolam (15 mg). Lidocaine 1% (3 mL) was used to infiltrate the skin and subcutaneous tissues at the L1-2 or L2-3 interspace. The epidural space was identified while patients were in the lateral decubitus position by use of an 18-gauge Tuohy needle and a loss of resistance to saline technique. After negative aspiration, patients were randomized to receive one of three blinded study solutions: 0.5% levobupivacaine without epinephrine, 0.5% levobupivacaine with 1:400,000 epinephrine, or 0.5% levobupivacaine with 1:200,000 epinephrine incrementally over a 3-min period (5-mL study drug "test dose," wait 2 min, 5-mL injection, wait 1 min, 5-mL injection). The initial total volume of study drug administered was 15 mL, providing a total dose of 75 mg.
The end of injection of study drug was termed "Time 0" for the purposes of subsequent patient assessment. A 20-gauge catheter was advanced 34 cm into the epidural space, and the needle was removed. If the height of sensory blockade failed to reach the T10 dermatome after 20 min, patients could be administered one re-dose with 5 mL of study drug if necessary. Intraoperative sedation was provided with additional IV midazolam and propofol (25100 µg · kg-1 · min-1) as needed at the discretion of the anesthesiologist. To assess the degree of anesthetic quality produced by the epidural drugs, neither IV muscle relaxants nor volatile anesthetics were used, and the patients were allowed to breathe spontaneously throughout the surgical procedure. Opiates and nonsteroidal antiinflammatory drugs were withheld until the patients first request for analgesic therapy in the postoperative period.
Epidural anesthetic blockade adequate to initiate surgery was defined as a sensory block bilaterally to dermatome T10. The primary efficacy measure was the duration of effective anesthesia, defined as the period of time from achieving bilateral T10 blockade to the time of bilateral regression to T10. Secondary efficacy measures included peak block height, time to reach peak block, time to two-segment regression, time to regression to T10, and time to complete regression (total duration of sensory block). Sensory block was measured with the blunt end of a 27-gauge dental needle at 0, 2, 5, 10, 15, 20, 25, 30, and 60 min after injection and every 30 min thereafter until complete regression of sensory block was observed.
The onset, degree, and duration of motor blockade were measured in both legs by using a modified Bromage scale and scored as "0" (no paralysis, full flexion of hips, knees, and ankles), "1" (inability to raise extended leg, able to move knees), "2" (inability to flex knees, able to flex ankles), or "3" (inability to move any portion of the lower limb). Motor block was mea-sured at 0, 10, and 20 min after dosing (before surgery) and every 30 min after surgery until the patient returned to a score of "0" in both legs.
The overall quality of intraoperative anesthetic quality (poor, fair, good, or excellent) was graded separately by the surgeon or anesthesiologist at the end of surgery.
Hemodynamic variables were recorded at baseline (preinjection), at the end of injection, and at 30-min intervals until complete resolution of the sensory block. Hypotension was defined as a decrease in systolic blood pressure of at least 30% from baseline and was treated with IV fluids or vasopressor drugs at the discretion of the attending anesthesiologist. Tachycardia was defined as a 30% increase in heart rate compared with baseline. All other adverse events were recorded throughout the study.
Venous blood samples were obtained from 30 patients who had received only 15 mL of solution (10 per group) at the end of injection, at 5, 10, 20, 30, 45, and 60 min after the end of injection, and at 2, 4, 6, 8, 10, and 12 h after the end of injection for pharmacokinetic analysis (Cmax, Tmax, t1/2, area under the plasma drug concentration-time curve, clearance, VD [volume of distribution]) of plasma levobupivacaine levels. Levobupivacaine levels were determined with liquid chromatography-mass spectrometry, with limits of determination of 10 ng/mL and coefficients of variation at these limits of approximately 0.8%.
All statistical comparisons were two tailed and performed on the intent-to-treat patient population, with significance set at P
0.05. Differences between groups were analyzed by using analysis of variance with pairwise comparisons, with 95% confidence intervals. Logistic regression analysis or
2 statistics were used to analyze categoric and incidence data. Kaplan-Meier survival analysis was used to compare the time to first request for postoperative analgesics.
| Results |
|---|
|
|
|---|
|
|
|
|
|
There were no differences in plasma concentrations of local anesthetic in patients who received plain levobupivacaine compared with patients in the Epinephrine-Containing groups (Fig. 3), with peak concentrations (Levobupivacaine, 0.36 ± 0.15 µg/mL; Levobupivacaine with 1:200,000 Epinephrine, 0.33 ± 0.19 µg/mL; Levobupivacaine with 1:400,000 Epinephrine, 0.25 ± 0.10 µg/mL; P = 0.21) occurring 0.84 ± 1.19 h, 1.02 ± 1.12 h, and 0.43 ± 0.29 h after the end of injection, respectively (Table 4, P = 0.39). The t1/2 and the area under the plasma drug concentration-time curve calculated did not significantly differ among groups (Table 4).
|
|
| Discussion |
|---|
|
|
|---|
Proposed disadvantages of regional anesthesia for lumbar spine surgery include the inability to immediately assess lower extremity motor function and a possible delay in bladder function. Yet, in this study, 53% of patients did not attain any degree of motor blockade.
This is the first study to evaluate the effect of adding epinephrine to epidural levobupivacaine. Our results are in agreement with previous studies looking at the effect of adding epinephrine to local anesthetic solutions. Both concentrations of epinephrine in this study decreased the peak plasma levobupivacaine concentrations, although this did not reach statistical significance. The 1:400,000 concentration also shortened the time required to reach this peak. Epinephrine consistently decreases peak plasma local anesthetic concentrations during epidural anesthesia, although it does not consistently reduce or prolong the time to reach these peak concentrations (4,810). Furthermore, vasoconstrictors have their greatest clinical effect on short-acting local anesthetics and do not always prolong the duration of blockade when added to long-acting drugs such as etidocaine or racemic bupivacaine (11).
Although a dose-response relationship of epinephrine added to local anesthetics has been established for subcutaneous (12) and intrathecal injections (13), this has not been established for the epidural injection of local anesthetics. In this study, two different concentrations of epinephrine were used. The addition of 2.5 µg/mL of epinephrine proved to be as effective as 5.0 µg/mL in reducing plasma levobupivacaine concentrations. Whether this is because levobupivacaine intrinsically produces a mild degree of vasoconstriction is not known. Both epinephrine concentrations also tended to increase the duration of sensory blockade above T10, although statistical significance was not reached for either (Levobupivacaine, 186 ± 67 minutes; Levobupivacaine with 1:200,000 Epinephrine, 202 ± 62 minutes; Levobupivacaine with 1:400,000 Epinephrine, 200 ± 67 minutes; P = 0.29).
Our results also show that the addition of either concentration of epinephrine to levobupivacaine increases the quality of intraoperative block as assessed by the anesthesiologist and surgeon. This increase in block density and reliability was also demonstrated when epinephrine (5 µg/mL) was added to racemic bupivacaine (14). According to multivariate analysis, the probability of a patient experiencing pain during surgery with epidural anesthesia is reduced by the addition of epinephrine (15).
The onset, peak block height, and regression of block in the patients who received the plain solution in this study are in agreement with previous studies in which plain 0.5% levobupivacaine was administered (16,17). All of these trials also confirm that effective clinical anesthesia is achieved with levobupivacaine and that the sensory blockade is substantially longer than any degree of motor blockade that may develop.
This study also confirms that levobupivacaine has a favorable profile with regard to adverse events. As expected, a decrease in systolic blood pressure, attributable to sympathetic blockade accompanying the epidural anesthesia, was the most common. Hemodynamic effects of epidural anesthesia are complex, because the volume, type, and concentration of local anesthetic, the level of blockade, the inclusion of vasoconstrictors, and physical status of the patient are all contributory. The addition of epinephrine generally produces a mild increase in heart rate and a greater decrease in blood pressure than plain epidural local anesthetics (4,8). In this study, reducing the concentration of epinephrine from 5.0 to 2.5 µg/mL decreased the incidence of hypotension to the same incidence as patients in the Plain Levobupivacaine group (from 23% to 10%), although this did not reach statistical significance (P = 0.08).
No cases of cardiac depression or central nervous system (CNS) toxicity caused by vascular absorption or direct intravascular injection of local anesthetic occurred in this study. One case of accidental intravascular injection of levobupivacaine (142.5 mg) has been reported, with the development of minimal CNS symptoms (transient agitation and disorientation) and no cardiovascular toxicity (18). In a study of 14 volunteers, the intentional intravascular administration (10 mg/min, until mild CNS symptoms developed) of levobupivacaine produced significantly fewer effects on myocardial function than racemic bupivacaine. Notably, changes in stroke index, acceleration index, and ejection fraction were less marked (19).
In conclusion, levobupivacaine is being developed as a local anesthetic with a similar pharmacodynamic profile to racemic bupivacaine, but with less risk of systemic toxicity. This study demonstrates that 0.5% levobupivacaine, with or without the addition of epinephrine, provides good epidural anesthesia for lumbar spine surgery, and all solutions are suitable for clinical use. The addition of epinephrine decreases plasma local anesthetic levels and improves intraoperative anesthetic quality. Decreasing the amount of added epinephrine from 5.0 to 2.5 µg/mL reduced the incidence of hypotension and tachycardia from 23% to 10% and 15% to 10%, respectively, although neither reduction was statistically significant.
| Acknowledgments |
|---|
The authors thank Jormain Cady, ARNP, Maureen Beaulieu, RN, Teresa Guthrie, RN, BSN, Pearl Washburn, RN, Rose Lopez, RN, and Jill Zeller, RN, for their assistance and dedication.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W. A. Visser, R. A. Lee, and M. J. M. Gielen Factors Affecting the Distribution of Neural Blockade by Local Anesthetics in Epidural Anesthesia and a Comparison of Lumbar Versus Thoracic Epidural Anesthesia Anesth. Analg., August 1, 2008; 107(2): 708 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ratajczak-Enselme, J.-P. Estebe, F.-X. Rose, E. Wodey, J.-M. Malinovsky, F. Chevanne, G. Dollo, C. Ecoffey, and P. Le Corre Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep Br. J. Anaesth., December 1, 2007; 99(6): 881 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Soetens, M. A. Soetens, and M. P. Vercauteren Levobupivacaine-sufentanil with or without epinephrine during epidural labor analgesia. Anesth. Analg., July 1, 2006; 103(1): 182 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. G. Costello, J. R. Cormack, L. E. Mather, B. LaFerlita, M. A. Murphy, and K. Harris Plasma levobupivacaine concentrations following scalp block in patients undergoing awake craniotomy Br. J. Anaesth., June 1, 2005; 94(6): 848 - 851. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Newton, G. A. McLeod, F. Khan, and J. J. F. Belch Vasoactive characteristics of bupivacaine and levobupivacaine with and without adjuvant epinephrine in peripheral human skin Br. J. Anaesth., May 1, 2005; 94(5): 662 - 667. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. McDonald, E. Jacobsohn, D. J. Kopacz, S. Desphande, J. D. Helman, F. Salinas, and R. A. Hall Parasternal Block and Local Anesthetic Infiltration with Levobupivacaine After Cardiac Surgery with Desflurane: The Effect on Postoperative Pain, Pulmonary Function, and Tracheal Extubation Times Anesth. Analg., January 1, 2005; 100(1): 25 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Tobias A Review of Intrathecal and Epidural Analgesia After Spinal Surgery in Children Anesth. Analg., April 1, 2004; 98(4): 956 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. B. Lee A Misleading Conclusion and Abstract Anesth. Analg., February 1, 2003; 96(2): 629 - 629. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|